RADT-41. THE ROLE OF RADIOTHERAPY IN RESECTED NON-SMALL CELL LUNG CANCER BRAIN METASTASES TREATED WITH CNS-ACTIVE TYROSINE KINASE INHIBITORS

Abstract For patients with non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs), the development of CNS-active tyrosine kinase inhibitors (CNS-TKIs) has transformed the treatment of brain metastases (BMs). For patients with resected BMs with AGAs, the benefits of adjuvant radiotherapy (RT) with TKI vs. TKI alone are unclear. Here we compare outcomes of patients with NSCLC with AGAs and resected BMs treated with CNS-TKIs, with and without adjuvant RT. We performed a retrospective analysis of consecutive patients with NSCLC with AGAs who underwent craniotomy for BMs at two institutions from March 2015 to June 2024. CNS-TKIs were defined as TKIs with >50% intracranial objective response rate in published studies. We identified 61 patients, 41 of whom received RT with a median collective follow-up of 29.3 months. AGAs included alterations in EGFR (n=42), ALK (9), ROS1 (4), MET (4), and RET (2), 77% of patients had gross total resection with no difference between groups (p=0.27). Patients receiving RT were more likely to have a single brain metastasis (p=0.046). Of patients undergoing RT, 20 received stereotactic radiotherapy (≤5 fractions), 18 had fractionated RT to the cavity (range 10-14 fractions), and 2 had hippocampal-avoidant whole brain RT (HA-WBRT). The 2-year rate of local recurrence (LR) with TKI alone was 18.3% vs, 3.2% with RT+TKI (p=0.011). There was no difference in 2-year intracranial recurrence (52.6% vs, 35.2%, p=0.31) or median overall survival (43.1 vs 43.5 months, p=0.50). Of 5 pts with LR, 3 required repeat craniotomy and postoperative RT; 1 received HA-WBRT. In this multi-institutional retrospective study, forgoing adjuvant RT for CNS-TKI alone was not associated with worse survival or intracranial recurrence but was associated with increased LR. More data are needed to understand the risks of LR and salvage treatments when treating patients with NSCLC resected BMs with AGAs.

Authors

Institutions

Publication Details

Journal
Neuro-Oncology
Published
2025-11-01
DOI
https://doi.org/10.1093/neuonc/noaf201.0410
Primary Topic
Brain Metastases and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

RADT-41. THE ROLE OF RADIOTHERAPY IN RESECTED NON-SMALL CELL LUNG CANCER BRAIN METASTASES TREATED WITH CNS-ACTIVE TYROSINE KINASE INHIBITORS

Shyam Kumar Tanguturi, Melin J. Khandekar, Daniel P. Cahill, Priscilla Kaliopi Brastianos et al.
Neuro-Oncology
Brain Metastases and Treatment
article

RADT-41. THE ROLE OF RADIOTHERAPY IN RESECTED NON-SMALL CELL LUNG CANCER BRAIN METASTASES TREATED WITH CNS-ACTIVE TYROSINE KINASE INHIBITORS

Shyam Kumar Tanguturi, Melin J. Khandekar, Daniel P. Cahill, Priscilla Kaliopi Brastianos, Sarah Waliany, Nayan Lamba, Ayal Aizer, Ariel E. Marciscano, Helen Alice Shih, Rifaquat Rahman, Henning Willers, Zofia Piotrowska, Florence K. Keane, Justin F. Gainor, Abrar Choudhury, Daphne Adele Haas-Kogan, Kevin Oh, Lin Zhu
article en

Abstract

Abstract For patients with non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs), the development of CNS-active tyrosine kinase inhibitors (CNS-TKIs) has transformed the treatment of brain metastases (BMs). For patients with resected BMs with AGAs, the benefits of adjuvant radiotherapy (RT) with TKI vs. TKI alone are unclear. Here we compare outcomes of patients with NSCLC with AGAs and resected BMs treated with CNS-TKIs, with and without adjuvant RT. We performed a retrospective analysis of consecutive patients with NSCLC with AGAs who underwent craniotomy for BMs at two institutions from March 2015 to June 2024. CNS-TKIs were defined as TKIs with >50% intracranial objective response rate in published studies. We identified 61 patients, 41 of whom received RT with a median collective follow-up of 29.3 months. AGAs included alterations in EGFR (n=42), ALK (9), ROS1 (4), MET (4), and RET (2), 77% of patients had gross total resection with no difference between groups (p=0.27). Patients receiving RT were more likely to have a single brain metastasis (p=0.046). Of patients undergoing RT, 20 received stereotactic radiotherapy (≤5 fractions), 18 had fractionated RT to the cavity (range 10-14 fractions), and 2 had hippocampal-avoidant whole brain RT (HA-WBRT). The 2-year rate of local recurrence (LR) with TKI alone was 18.3% vs, 3.2% with RT+TKI (p=0.011). There was no difference in 2-year intracranial recurrence (52.6% vs, 35.2%, p=0.31) or median overall survival (43.1 vs 43.5 months, p=0.50). Of 5 pts with LR, 3 required repeat craniotomy and postoperative RT; 1 received HA-WBRT. In this multi-institutional retrospective study, forgoing adjuvant RT for CNS-TKI alone was not associated with worse survival or intracranial recurrence but was associated with increased LR. More data are needed to understand the risks of LR and salvage treatments when treating patients with NSCLC resected BMs with AGAs.

Neuro-OncologyVol. 27(Supplement_5)
Brigham and Women's Hospital (US), Harvard University (US), Massachusetts General Hospital (US), Harvard Affiliated Emergency Medicine Residency (US), Dana-Farber/Harvard Cancer Center (US), Radiation Oncology Associates (US)
Openalex Percentile: Top 51%
Brain Metastases and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.